GSK to buy US lung cancer drug specialist Nuvalent for £8bn
The acquisition is thought to be GSK’s biggest deal in more than a decade.
GSK Acquires Nuvalent for $10.6 Billion
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down MarketWatch —
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn The Guardian —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Independent —
- GSK agrees to buy US cancer drug firm Nuvalent in £8bn deal Yorkshire Post —